AzTrials
AzTrials

Osteoarthritis, KneeMOBILIZENCT04645732

Personalized Exercise Therapy and Self-management Support for Patients With Multimorbidity

A study testing Personalized exercise therapy and self-management support program in people with Osteoarthritis, Knee and Osteoarthritis, Hip, run by University of Southern Denmark at 16 sites in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Chronic conditions such as knee or hip osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), heart failure (HF), coronary heart disease (CHD), hypertension, type 2 diabetes mellitus (T2DM) and depression are among the leading causes of global disability and affect hundreds of millions of people around the… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Personalized exercise therapy and self-management support program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
228 participants
Where
16 sitesDenmark
Study dates
1 Nov 2021to 31 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • At least two of the following conditions: OA (knee or hip), COPD, heart condition (HF or CHD), hypertension, T2DM, depression (having other comorbidities does not exclude a patient)
  • Adults aged 18 years or above
  • Able to walk 3 meters without any assistance
  • A score of 3 or above on the Bayliss' Disease Burden: Morbidity Assessment by Self- Report scale for at least one of the conditions listed above and a score of 2 or above for at least one of the other listed conditions
  • Willingness and ability to participate in a 12-week supervised exercise therapy and self- management support program twice a week

Who cannot join

  • Participation in supervised systematic exercise for one of their diseases within the last 3 months
  • Patients with an unstable health condition or at risk of serious adverse events as evaluated by a medical specialist
  • Patients categorized as Class IV on the New York Heart Association (NYHA) Functional Classification scale
  • Terminal patients and patients with life expectancy of less than 12 months
  • Patients with psychosis disorders, post-traumatic stress disorder, Obsessive Compulsive Disorder, attention deficit hyperactivity disorder, autism, anorexia nervosa/bulimia nervosa and patients with dependency disorders
  • Other reasons (unable to understand Danish, mentally unable to participate, etc.)

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

Denmark16 sites
  • Holbæk Sygehus

    Holbæk

  • Læge Poul Erik Holst

    Holbæk

  • Lægehuset Tolskovvej

    Kirke Hvalsø

  • Department of Orthopedics, Zealand University Hospital

    Køge

  • Department of Orthopaedic Surgery, Næstved Hospital

    Næstved

  • Department of Pulmonology, Næstved Hospital

    Næstved

  • Lægehuset Ostenfeldt

    Næstved

  • Psychiatric Clinic Næstved

    Næstved

  • Community Clinic

    Nakskov

  • Community Psychiatry Roskilde

    Roskilde

  • Department of Cardiology, Zealand University Hospital

    Roskilde

  • Lægerne Algade 17

    Roskilde

  • Department of Cardiology and Endocrinology, Slagelse Hospital

    Slagelse, 4200

  • Lægerne Reventlow og Wolfhagen

    Slagelse, 4200

  • Psychiatric Hospital West, Slagelse

    Slagelse, 4200

  • Nykøbing Falster County Hospital

    Slagelse

Other trials in Denmark

About this study

Official title: Improving Health in People With Multimorbidity: a Paradigm Shift in Health Care From Disease-based Curative Models to Personalized Exercise Therapy and Self-management

Chronic conditions such as knee or hip osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), heart failure (HF), coronary heart disease (CHD), hypertension, type 2 diabetes mellitus (T2DM) and depression are among the leading causes of global disability and affect hundreds of millions of people around the world. In recent years, multimorbidity, commonly defined as the co-occurrence of at least two chronic conditions, has also gained interest due to its substantial impact on the person and society.

Despite the significant burden of multimorbidity, little is known about how to treat this effectively. A 2016 Cochrane systematic review found that interventions targeting populations with specific combinations of conditions and addressing specific problems such as functional difficulties may be more effective. Exercise therapy is a treatment addressing functional limitations that is a safe and effective treatment of at least 26 chronic conditions, including OA, HF, CHD, hypertension, T2DM, COPD and depression. Furthermore, self-management support is increasingly recognized as an essential component of interventions to improve outcomes in patients living with multimorbidity and to support the long-term adherence to exercise. A new systematic review found that exercise seems effective in people with multimorbidity (the conditions included in the current study), however highlighting the need for further high-quality RCTs.

Read more

The aim of this randomized controlled trial (RCT) is to investigate the effects of a personalized exercise therapy and self-management support program in addition to usual care on self-reported, objectively measured and physiological outcomes in people with multimorbidity (i.e. at least two of the following conditions: OA (knee or hip), heart condition (HF or CHD), hypertension, T2DM, COPD and depression). The primary endpoint is 12 months, but 4- and 6-month follow-ups are included as well and a 12-month health economic evaluation of the program will be conducted.

Prior to the RCT, a feasibility trial of 20 people with multimorbidity, all undergoing the personalized exercise therapy and self-management support program, will be conducted using the same methods as in the RCT, but primarily focusing on feasibility outcomes (recruitment, retention, adherence to treatment, burden of outcomes, improvements in outcomes, adverse events). This will start recruitment in Feb 2021 and end August 2021.

The MOBILIZE project has received funding from several foundations, including the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 801790).

Read the detailed description

Chronic conditions such as knee or hip osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), heart failure (HF), coronary heart disease (CHD), hypertension, type 2 diabetes mellitus (T2DM) and depression are among the leading causes of global disability and affect hundreds of millions of people around the world. In recent years, multimorbidity, commonly defined as the co-occurrence of at least two chronic conditions, has also gained interest due to its substantial impact on the person and society. In general, multimorbidity affects more than half of all people with chronic conditions. Two out of three people with OA have comorbidities, with HF, CHD, hypertension, T2DM, COPD and depression being some of the most common.

People with multimorbidity account for 78% of all consultations in primary care and multimorbidity is associated with poorer function and quality of life, depression, intake of multiple drugs and increased health care utilization, with some studies demonstrating an almost exponential relationship between the number of chronic conditions and their health care costs. Furthermore, we know from qualitative research that treating one condition at a time is inconvenient, inefficient and unsatisfactory for the person with the chronic conditions and his or her health care provider. Most research so far has excluded people with multimorbidity, due to its focus on only one specific condition, and most of the health care sector manages each individual condition on its own instead of the person, highlighting the negative impact of the current disease-based curative models on multimorbidity. With a population that is ageing, and a significant number of people with multimorbidity being younger than 65 years of age, the proportion of people with multimorbidity is increasing rapidly, emphasizing the need to take action to deal with the increasing burden of chronic conditions and multimorbidity through treatment and prevention.

Identifying and developing effective and affordable treatment strategies to deal with the global burden of chronic conditions and multimorbidity is a major focus of modern health care around the world. Despite the significant burden of multimorbidity, little is known about how to treat this effectively. A 2016 Cochrane systematic review found that interventions targeting populations with specific combinations of conditions and addressing specific problems such as functional difficulties may be more effective. A treatment addressing functional limitations that is able to improve symptoms in at least 26 chronic conditions, including OA, HF, CHD, hypertension, T2DM, COPD and depression is readily available. This treatment is exercise therapy, which is effective, safe and supported by substantial evidence in patients with knee and hip OA, HF and CHD, hypertension, T2DM, COPD, depression and a range of other chronic conditions. A new systematic review found that exercise seems effective in people with multimorbidity (the conditions included in the current study), however highlighting the need for further high-quality RCTs. Furthermore, self-management support is increasingly recognized as an essential component of interventions to improve outcomes in patients living with multimorbidity. There is increasing evidence that effective management of multimorbidity requires the active participation by patients in the care process. Self-management support interventions have been shown to change health behaviors, improve health status, and reduce health care utilization and costs. Self-management support is centered on enabling patients to develop a set of behavioral skills and abilities to help them navigate a range of disease management tasks across different chronic conditions.

In an RCT of people with knee OA, published in the New England Journal of Medicine, we found that 3 out of 4 patients eligible for total knee replacement improved enough from self-management support, supervised exercise therapy and other non-surgical treatments to postpone surgery for at least one year. Furthermore, in patients with T2DM, 56% did not take antidiabetic medication after 1 year of supervised exercise therapy, self-management support and diet. Together, these studies indicate the potential of combining exercise, self-management and other treatments to reduce the need for surgery and medication. A recent cohort study found that an eight-week exercise and self-management program demonstrated similar improvements in health outcomes for people with OA and the comorbidities included in the current study as for people without comorbidities.

Altogether, this highlights exercise therapy and self-management support as viable treatment options for people with multimorbidity, but the evidence supporting this is of low quality and more high-quality RCTs are needed to improve care for the millions of people suffering from multimorbidity worldwide.

The overall aim of the MOBILIZE project is to empower patients with multimorbidity to take a more active role in their health care through a personalized exercise therapy and self-management support program so that they may reduce symptoms of the individual conditions, increase quality of life and physical function and prevent development of other chronic conditions. To ensure relevance to the patients and the health care system and to make sure that the project is implementable in clinical practice afterwards, strong interdisciplinary collaboration involving many different scientific methodologies and a high degree of patient involvement throughout the entire research process are at the heart of the project. The MOBILIZE project has received funding from several foundations, including the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 801790). Building on the Medical Research Council's framework for the development and evaluation of complex interventions, the MOBILIZE project has four phases. During the first phase of the project, outcomes and biomarkers that predict better health outcome from different types of exercise therapy and exercise characteristics associated with a better outcome in people with different combinations of chronic conditions will be identified through exploratory observational cohort studies of people with osteoarthritis who have undergone an 8-week exercise therapy and education program in Denmark (GLA:D) as well as scoping reviews, systematic reviews and meta-analyses that summarize the existing evidence. Subsequently, in phase 2, a 12-week exercise therapy and self-management support program will be developed based on existing recommendations for exercise and strategies to facilitate behavioral changes. To ensure a high degree of patient and provider involvement, focus group interviews will be conducted with patients with multimorbidity, health care providers and other relevant stakeholders to acquire their views and perspectives on multimorbidity and exercise. Once this phase is completed, the exercise therapy and self-management support program will be tested in a feasibility trial involving 20 patients with multimorbidity (recruited from Feb 2021 and onwards). The same procedures and outcomes as in the subsequent RCT will be used, and data will be collected at baseline and after the 12-week intervention. The feasibility trial will primarily focus on feasibility outcomes (recruitment, retention, adherence to treatment, burden of outcomes, improvements in outcomes, adverse events), using a red/amber/green traffic light system, guiding the progression to the subsequent RCT. Experiences from the feasibility trial will be used to evaluate and implement any adjustments that need to be made prior to commencing the RCT (described in details in the current trial registration). The RCT corresponds to phase 3, while phase 4 focuses on developing a model for implementation of the personalized exercise therapy and self-management support program in clinical practice, if supported by the study findings.

The aim of the RCT described in this clinical trial registration is to investigate the effects of a personalized exercise therapy and self-management support program in addition to usual care on self-reported, objectively measured and physiological outcomes in people with multimorbidity (i.e. at least two of the following conditions: OA (knee or hip), heart condition (HF or CHD), hypertension, T2DM, COPD and depression). The primary endpoint is 12 months, but 4- and 6-month follow-ups are included as well and a 12-month health economic evaluation of the program will be conducted. The 4-month follow-up corresponds to immediately after the intervention, including the time it takes to conduct the baseline measurements and be enrolled in the group-based program.

The primary study hypothesis is that a personalized exercise therapy and self-management support program in addition to usual care will improve quality of life more than usual care alone when measured at 12 months with concurrent positive effects on secondary outcomes. Furthermore, it is hypothesized that the program will be cost-effective at 12 months.

People will be recruited via the recruitment centers mentioned in this registration as well as via self-referral (Facebook posts, newspaper articles and flyers).

People who only fulfil some of the eligibility criteria (aged 18 years or above, at least two of the relevant conditions and do not have psychosis disorders, post-traumatic stress disorder, Obsessive Compulsive Disorder, attention deficit hyperactivity disorder, autism, anorexia nervosa/bulimia nervosa or an abuse or other reasons for exclusion) or people fulfilling all eligibility criteria, but unwilling to participate in the RCT, will be offered participation in an observational cohort study where only the self-reported outcomes are completed. Recruitment for the cohort will start and end with the recruitment for the RCT.

Being tested
Personalized exercise therapy and self-management support program, Usual care
Keywords
Exercise, Self-management, Clinical Trial, Multimorbidity, Evaluation
Medical subject headings
Osteoarthritis, Knee, Osteoarthritis, Hip, Heart Failure, Coronary Disease, Hypertension, Pulmonary Disease, Chronic Obstructive, Depression, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personalized exercise therapy and self-management support programBehavioural

    See description under Arms

  • Usual careOther

    See description under Arms

Study groups in NCT04645732
Study groupRoleWhat they receive
Personalized exercise therapy and self-management program in addition to usual careExperimentalParticipants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour). Furthermore, this group will receive the treatment described under usual care below.
Receives: Behavioral: Personalized exercise therapy and self-management support program; Other: Usual care
Usual care aloneActive comparatorUsual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
Receives: Other: Usual care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EQ-5D-5L, the descriptive index

    The descriptive index of the EuroQol-5 Domain 5-level questionnaire (EQ-5D-5L) measures the patient's self-rated health status. Ranging from -0.757 to 1, higher is better. This will also allow for a later cost-effectiveness analysis. Assessed at baseline, 4, 6 and 12 months. All visits (baseline, 4, 6 and 12 months) will be included in the analysis.

    Measured: Primary endpoint: Change from baseline to 12 months

Secondary outcomes (12)
  1. 6-minute walk test

    The walking distance covered over a time of 6 minutes. Assessed at baseline, 4 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  2. Burden of illness measure

    The burden of illness measure developed by Bayliss et al. measures how much illness affects the individual's daily activities (on a 1-5 scale for each individual condition, higher is worse, summed to a total score for all conditions, with an upper limit depending on the number of conditions included). Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  3. 30-second chair-stand test

    The number of chair stands completed in 30 seconds. Assessed at baseline, 4 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  4. Depression Scale

    Personal Health Questionnaire Depression Scale (PHQ-8). Ranging from 0-24 points, higher is more severe depression. Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  5. Anxiety

    General Anxiety Disorder-7 (GAD-7). Ranging from 0-21, higher is more severe anxiety. Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  6. Self-Efficacy

    Self-Efficacy for Managing Chronic Disease 6-item Scale. Mean of 6 items, ranging from 1 to 10, higher scores indicating higher self-efficacy. Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  7. Overall functioning and disability

    12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). Ranging from 0 (no disability) to 100 (full disability). Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  8. Adverse events

    Adverse events (AE) and serious adverse events (SAE) will be recorded at all follow-ups by asking the participants about potential AEs using open-probe questioning to ensure that all AEs are recorded. Furthermore, the medical records of the patients will be checked at the primary endpoint (12 months) for all AEs occurring from inclusion until the 12 months follow-up. AEs will be classified according to the Food and Drug Administration definition of an SAE and recorded, categorized and assessed for severity independent of whether or not there is a causal relationship with study treatments. Assessed at 4, 6 and 12 months.

    Measured: Primary endpoint: 12 months

  9. Steps per day

    Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  10. Minutes/day spent being physically active with at least light intensity

    Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  11. EQ-5D-5L, the subscale EQ VAS

    The EQ visual analogue scale (EQ VAS) evaluates the patient's self-rated health on a 0-100 vertical visual analogue scale, higher score is better. Assessed at baseline, 4, 6 and 12 months.

    Measured: Primary endpoint: Change from baseline to 12 months

  12. Mortality

    Mortality will be recorded at 12 months via medical records

    Measured: Primary endpoint: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Nov 2020
  2. Study start1 Nov 2021
  3. Primary completion31 Jul 2024
  4. Study completion31 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The RCT is a pragmatic, parallel-group, superiority RCT (1:1 ratio)
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
228 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04645732
Sponsor's protocol ID
SJ-857
Other IDs
801790
Acronym
MOBILIZE
Status last verified
Aug 2024
First submitted
2 Nov 2020
Last updated
23 Aug 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be made available upon reasonable request after the primary publications have been published.

Publications

  • Skou ST, Nyberg M, Dideriksen M, Rasmussen H, Overgaard JA, Bodilsen C, Soja AMB, Attarzadeh AP, Bieder MJ, Dridi NP, Heltberg A, Gaede PH, Reventlow JL, Arnfred S, Bodtger U, Brond JC, Thygesen LC, Moller SP, Jager M, Bricca A. Exercise therapy and self-management support for individuals with multimorbidity: a randomized and controlled trial. Nat Med. 2025 Sep;31(9):3176-3182. doi: 10.1038/s41591-025-03779-4. Epub 2025 Jun 30.

    PubMed 40588675
  • Skou ST, Brodsgaard RH, Nyberg M, Dideriksen M, Bodtger U, Bricca A, Jager M. Personalised exercise therapy and self-management support for people with multimorbidity: feasibility of the MOBILIZE intervention. Pilot Feasibility Stud. 2023 Jan 18;9(1):12. doi: 10.1186/s40814-023-01242-0.

    PubMed 36653858

Questions about this trial

What is this clinical trial studying?

A study testing Personalized exercise therapy and self-management support program in people with Osteoarthritis, Knee and Osteoarthritis, Hip, run by University of Southern Denmark at 16 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EQ-5D-5L, the descriptive index (time frame: Primary endpoint: Change from baseline to 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04645732, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in